公开(公告)号：US08876758B2

公开(公告)日：2014-11-04

申请号：US13089884

申请日：2011-04-19

申请人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30 ,  A61M31/00 ,  A61K9/00 ,  A61M5/20

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中获益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US20110196336A1

公开(公告)日：2011-08-11

申请号：US13089884

申请日：2011-04-19

申请人： Brooks M. BOYD ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. BOYD ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中受益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US09186461B2

公开(公告)日：2015-11-17

申请号：US13562596

申请日：2012-07-31

申请人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30 ,  A61K9/00 ,  A61M5/20

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second ±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中获益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US08066661B2

公开(公告)日：2011-11-29

申请号：US12032044

申请日：2008-02-15

申请人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中获益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US20120296270A1

公开(公告)日：2012-11-22

申请号：US13562596

申请日：2012-07-31

申请人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中获益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US20080214995A1

公开(公告)日：2008-09-04

申请号：US12032044

申请日：2008-02-15

申请人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

发明人： Brooks M. Boyd ,  Sujata Mudumba ,  Stephen J. Farr

IPC分类号： A61M5/30

CPC分类号： A61M5/30 ,  A61K9/0021 ,  A61K9/0024 ,  A61M5/2053 ,  A61M37/0069

摘要： Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.

摘要翻译： 描述了粘稠的制剂，并且将在高驱动压力下从无针运送中受益。 通过皮下注射器常规递送这些粘稠制剂是不方便和痛苦的。 制剂包括在约20℃下具有约5cS或更高的粘度的那些，其可以在约0.1秒±0.02秒内通过无针注射器施用0.5ml或更多。

公开(公告)号：US20160199579A1

公开(公告)日：2016-07-14

申请号：US13823003

申请日：2012-01-09

申请人： Brooks Boyd ,  Stephen J. Farr ,  Jeffery A. Schuster ,  Andy Fry ,  Andy Pocock ,  Brennan Miles ,  Chris Hurlstone ,  Joe Daintrey

发明人： Brooks Boyd ,  Stephen J. Farr ,  Jeffery A. Schuster ,  Andy Fry ,  Andy Pocock ,  Brennan Miles ,  Chris Hurlstone ,  Joe Daintrey

IPC分类号： A61M5/30 ,  A61M5/20

CPC分类号： A61M5/30 ,  A61M5/2053 ,  A61M2005/2073 ,  A61M2005/3104

摘要： Improved needle free injectors comprising of a energy sources, triggering mechanisms, impact members, and drug delivery pistons are disclosed. In one preferred embodiment, the triggering mechanism comprises a spool which seals an energy source comprised of compressed gas and a component for releasing the spool to release the pressurized gas and urge a ram forward to force a drug containing formulation through a drug delivery orifice. The device may include a cap covering the orifice and safety mechanisms to prevent accidental delivery

摘要翻译： 公开了包括能量源，触发机构，冲击构件和药物递送活塞的改进的无针注射器。 在一个优选实施例中，触发机构包括一个线轴，其密封由压缩气体构成的能量源和用于释放线轴的部件以释放加压气体，并且向前推动压头以迫使含药制剂通过药物输送孔。 该装置可以包括覆盖孔的盖和安全机构以防止意外的传送

公开(公告)号：US20110118189A1

公开(公告)日：2011-05-19

申请号：US12937355

申请日：2009-04-24

申请人： Stephen J. Farr ,  John Turanin ,  Roger Hawley ,  Jeffrey A. Schuster

发明人： Stephen J. Farr ,  John Turanin ,  Roger Hawley ,  Jeffrey A. Schuster

IPC分类号： A61K38/16 ,  A61P25/06 ,  A61P1/08 ,  A61K31/404 ,  A61K31/403 ,  A61K31/454 ,  A61K31/48 ,  A61K31/616 ,  A61K31/485 ,  A61K31/5415 ,  A61K31/56 ,  A61P25/24 ,  A61K31/439

CPC分类号： A61M5/30 ,  A61K9/0019 ,  A61K9/0021 ,  A61K9/0024 ,  A61K9/16 ,  A61K31/4045 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/44 ,  A61K31/454 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/24 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36

摘要： Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.

摘要翻译： 描述了用于治疗偏头痛和相关病症如丛集性头痛的不满足的医疗需求的系统和方法。 包括快速发作和长效的治疗，包括持续释放制剂和组合产品。 还包括治疗偏头痛的多种症状，特别是头痛，恶心和呕吐。 公开了在偏头痛发作开始时是自包含的，便携式的，预填充的和易于自我施用的系统，并且优选地包括无针注射器和高粘度制剂，以消除诸如担心自身给药的问题 ，针刺和交叉污染。

公开(公告)号：US5884620A

公开(公告)日：1999-03-23

申请号：US846243

申请日：1997-04-25

申请人： Igor Gonda ,  Reid M. Rubsamen ,  Stephen J. Farr

发明人： Igor Gonda ,  Reid M. Rubsamen ,  Stephen J. Farr

IPC分类号： A61M11/02 ,  A61J7/04 ,  A61K9/00 ,  A61K38/28 ,  A61M15/00 ,  A61M16/00 ,  A61M16/14 ,  A61M11/00

CPC分类号： A61K9/007 ,  A61K38/28 ,  A61K9/0073 ,  A61M11/001 ,  A61M15/00 ,  A61M15/0031 ,  A61M15/0043 ,  A61M15/0045 ,  A61M15/0051 ,  A61M15/0066 ,  A61M15/008 ,  A61M16/142 ,  A61J7/0418 ,  A61J7/0427 ,  A61J7/0445 ,  A61M15/0085 ,  A61M15/009 ,  A61M2016/0021 ,  A61M2016/0036 ,  A61M2202/062 ,  A61M2202/064 ,  A61M2205/50 ,  A61M2205/8206 ,  Y10S514/866

摘要： Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.

公开(公告)号：US07490603B2

公开(公告)日：2009-02-17

申请号：US11284579

申请日：2005-11-21

申请人： Igor Gonda ,  Reid M. Rubsamen ,  Stephen J. Farr

发明人： Igor Gonda ,  Reid M. Rubsamen ,  Stephen J. Farr

IPC分类号： A61M11/00

CPC分类号： A61K9/007 ,  A61J7/0418 ,  A61J7/0427 ,  A61J7/0445 ,  A61K9/0073 ,  A61K9/0075 ,  A61K38/28 ,  A61M11/001 ,  A61M15/00 ,  A61M15/0031 ,  A61M15/0045 ,  A61M15/0051 ,  A61M15/0065 ,  A61M15/0066 ,  A61M15/008 ,  A61M15/0085 ,  A61M15/009 ,  A61M16/142 ,  A61M2016/0021 ,  A61M2016/0036 ,  A61M2202/062 ,  A61M2202/064 ,  A61M2205/50 ,  A61M2205/8206

摘要： The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.